Lund Melanoma Study Group
91 – 100 of 258
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
BRN2 is a non-canonical melanoma tumor-suppressor
- Contribution to journal › Article
-
Mark
The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy : A Population-Based Cohort Study
- Contribution to journal › Article
-
Mark
Difference in Sun Exposure Habits Between Individuals with High and Low Risk of Skin Cancer
- Contribution to journal › Article
-
Mark
Trend shifts in age-specific incidence for in situ and invasive cutaneous melanoma in sweden
- Contribution to journal › Article
-
Mark
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
- Contribution to journal › Article
-
Mark
Mendelian randomisation study of smoking exposure in relation to breast cancer risk
- Contribution to journal › Article
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
- Contribution to journal › Article
-
Mark
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
- Contribution to journal › Article
-
Mark
Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine
- Contribution to journal › Article
-
Mark
Non-radical primary diagnostic biopsies affect survival in cutaneous head and neck melanoma
- Contribution to journal › Article
